IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James

IO Biotech, Inc.

Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.
Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.
Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.
Company implementing significant global workforce reduction to reduce operating expenses.

item 2.05 item 5.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-031987
form_type: 8-K
ticker: IOBTQ
cik: 0001865494
company_name: IO Biotech, Inc.
filed_at: 2026-01-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.604519+00:00
generated_at: 2026-05-16T06:05:48.092427+00:00
sec_items: ["2.05", "5.02", "8.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-031987
json_url: https://secwatch.observer/filing/0001193125-26-031987.json
markdown_url: https://secwatch.observer/filing/0001193125-26-031987.md
text_url: https://secwatch.observer/filing/0001193125-26-031987.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/0001193125-26-031987-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/d13704d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-031987

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.